Literature DB >> 18246524

Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.

William J Peppard1, Christopher D Schuenke.   

Abstract

Arpida Ltd, under license from Roche AG, is developing the diaminopyrimidine dihydrofolate reductase inhibitor iclaprim for the potential treatment of methicillin-resistant Staphylococcus aureus infections, including complicated skin and skin structure infections and hospital-acquired pneumonia. Phase III cSSSI clinical trials have been completed and an NDA filing process is ongoing. A phase II clinical trial for hospital-acquired pneumonia is ongoing.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18246524

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  8 in total

1.  Temperature dependence of protein motions in a thermophilic dihydrofolate reductase and its relationship to catalytic efficiency.

Authors:  Olayinka A Oyeyemi; Kevin M Sours; Thomas Lee; Katheryn A Resing; Natalie G Ahn; Judith P Klinman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-13       Impact factor: 11.205

Review 2.  Advances in MRSA drug discovery: where are we and where do we need to be?

Authors:  Michio Kurosu; Shajila Siricilla; Katsuhiko Mitachi
Journal:  Expert Opin Drug Discov       Date:  2013-07-06       Impact factor: 6.098

3.  In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.

Authors:  Karen E Bowker; Patrick Caspers; Bérengère Gaucher; Alasdair P MacGowan
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

4.  Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.

Authors:  Helio S Sader; Thomas R Fritsche; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

5.  In vitro bactericidal activity of iclaprim in human plasma.

Authors:  Heike Laue; Tiziana Valensise; Aurélie Seguin; Sergio Lociuro; Khalid Islam; Stephen Hawser
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191

6.  Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections.

Authors:  D Krievins; R Brandt; S Hawser; P Hadvary; K Islam
Journal:  Antimicrob Agents Chemother       Date:  2009-05-04       Impact factor: 5.191

Review 7.  Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors.

Authors:  Agnieszka Wróbel; Karolina Arciszewska; Dawid Maliszewski; Danuta Drozdowska
Journal:  J Antibiot (Tokyo)       Date:  2019-10-02       Impact factor: 2.649

Review 8.  Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.

Authors:  Despoina Koulenti; Elena Xu; Andrew Song; Isaac Yin Sum Mok; Drosos E Karageorgopoulos; Apostolos Armaganidis; Sotirios Tsiodras; Jeffrey Lipman
Journal:  Microorganisms       Date:  2020-01-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.